Literature DB >> 11277519

NO-independent stimulators of soluble guanylate cyclase.

A Straub1, J P Stasch, C Alonso-Alija, J Benet-Buchholz, B Ducke, A Feurer, C Fürstner.   

Abstract

SARs around a novel type of guanylate cyclase stimulator which act by a mechanism different from classical NO-donors are described. Several pyrazolopyridinylpyrimidines are shown to relax aortic rings and revealed a long-lasting blood pressure lowering effect in rats after oral application.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11277519     DOI： 10.1016/s0960-894x(01)00073-7

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  36 in total

1.  Soluble guanylate cyclase is activated differently by excess NO and by YC-1: resonance Raman spectroscopic evidence.

Authors:  Mohammed Ibrahim; Emily R Derbyshire; Alexandra V Soldatova; Michael A Marletta; Thomas G Spiro
Journal:  Biochemistry       Date:  2010-06-15       Impact factor: 3.162

2.  Soluble guanylate cyclase: an old therapeutic target re-visited.

Authors:  Adrian J Hobbs
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

Review 3.  cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.

Authors:  Sharron H Francis; Jennifer L Busch; Jackie D Corbin; David Sibley
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

Review 4.  Novel therapeutic targets for hypertension.

Authors:  Ludovit Paulis; Thomas Unger
Journal:  Nat Rev Cardiol       Date:  2010-06-22       Impact factor: 32.419

Review 5.  NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential.

Authors:  Oleg V Evgenov; Pál Pacher; Peter M Schmidt; György Haskó; Harald H H W Schmidt; Johannes-Peter Stasch
Journal:  Nat Rev Drug Discov       Date:  2006-09       Impact factor: 84.694

Review 6.  Novel therapies for cyclic GMP control of vascular smooth muscle growth.

Authors:  David A Tulis
Journal:  Am J Ther       Date:  2008 Nov-Dec       Impact factor: 2.688

7.  Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies.

Authors:  Johannes-Peter Stasch; Cristina Alonso-Alija; Heiner Apeler; Klaus Dembowsky; Achim Feurer; Torsten Minuth; Elisabeth Perzborn; Matthias Schramm; Alexander Straub
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

8.  Insight into the rescue of oxidized soluble guanylate cyclase by the activator cinaciguat.

Authors:  Nur Basak Surmeli; Michael A Marletta
Journal:  Chembiochem       Date:  2012-03-30       Impact factor: 3.164

Review 9.  Soluble guanylate cyclase: a potential therapeutic target for heart failure.

Authors:  Mihai Gheorghiade; Catherine N Marti; Hani N Sabbah; Lothar Roessig; Stephen J Greene; Michael Böhm; John C Burnett; Umberto Campia; John G F Cleland; Sean P Collins; Gregg C Fonarow; Phillip D Levy; Marco Metra; Bertram Pitt; Piotr Ponikowski; Naoki Sato; Adriaan A Voors; Johannes-Peter Stasch; Javed Butler
Journal:  Heart Fail Rev       Date:  2013-03       Impact factor: 4.214

10.  Stimulators of soluble guanylyl cyclase: future clinical indications.

Authors:  Bobby D Nossaman; Philip J Kadowitz
Journal:  Ochsner J       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.